Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03348020
Other study ID # HUM00138926
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2018
Est. completion date February 28, 2020

Study information

Verified date March 2022
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine the effects of reducing whole-body iron stores in overweight/obese subjects (via one-time blood donation) on adipose tissue iron content, factors regulating iron homeostasis and lipolytic rate in adipose tissue, as well as measures of adipose tissue and whole-body insulin resistance. After a screening visit to determine eligibility, subjects will undergo a battery of tests for the determination of primary outcome measures at baseline. They will then donate 1 unit (~500 mL) of blood (at a local blood donation center) and return for a follow-up testing 4 weeks after blood donation. During the 4-week period between study trials, subjects will be required to maintain a stable body mass and not alter their dietary or physical activity habits.


Description:

Screening: If a potential subject meets the eligibility criteria after completing the general pre-screening questionnaire, they will be contacted to set up an in-person screening visit where the comprehensive written informed consent will be obtained. This visit may occur either at the Michigan Clinical Research Unit (MCRU) or at the Substrate Metabolism Laboratory (SML). Subjects will complete health history, food frequency, and physical activity questionnaires. Subjects that meet eligibility requirements and provide written informed consent will have a finger-stick performed for the assessment of hemoglobin concentration. Women with hemoglobin < 13.0 g/dL and men with hemoglobin < 14.0 g/dL will be withdrawn from the study. Percent body fat will be measured using Dual Energy X-ray Absorptiometry [DEXA]. Women will provide a urine sample for a urine pregnancy test prior to the DEXA scan; if a subject has a positive pregnancy test prior to the DEXA scan, they will be withdrawn. The DEXA body composition assessment test may be performed at the screening visit or scheduled anytime between the screening visit and the baseline trial. Baseline Trial: Subjects will be provided general instructions on what to eat in the 3 days leading up to their baseline trial and be required to abstain from planned exercise in the 3 days leading up to the baseline and post-blood donation study trials. They will record their dietary intake during the 3 days leading up to the baseline trial and replicate it during the 3 days prior to the post-blood donation study trial. They will be required to fast the night before the trials starting at 9:00PM. Subjects will arrive at MCRU at ~07:00AM. After measurement of body weight and resting blood pressure, intravenous catheters (IV) will be placed in each arm (one for blood sampling and the other for infusion). At ~7:50 AM blood samples (in 5 minute intervals) will be collected. A ~8:00 AM a tracer-labeled glycerol infusion will begin. The tracer-labeled glycerol infusion that is infused occurs naturally in the body. By injecting a slightly greater amount of this substance than is already in the body, the rate of fat breakdown and fat burning is able to be measured. One of the subject's hands will be placed within a "hot-hand box" to enable the study team to collect arterialized venous blood samples from the intravenous catheter. At ~08:30AM, a small sample of abdominal fat tissue will be collected. Between ~09:50 and 10:00, three blood samples will be collected to determine basal lipolysis. At ~10:00, we will start the hyperinsulinemic, euglycemic clamp procedure to measure the body's sensitivity to insulin. During this procedure insulin and glucose will be infused through the IV in the forearm and blood samples will be collected periodically to monitor the subjects blood sugar. The infusion rate of glucose will be changed accordingly to ensure that the subjects blood sugar is maintained at a healthy/normal level. This procedure will take about two hours. Following completion, The insulin will be discontinued and the subject will be provided a lunch and the glucose will be gradually tapered off over the next hour. The study team will ensure the subjects blood glucose levels are stable prior to discharge. Blood Donation: Subjects will donate blood within ~1 month after their baseline trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration. Post-Blood Donation Trial: The exact same procedures as performed in the Baseline Trial will be repeated 4 weeks after the subject's blood donation. Diet/Physical Activity/Weight Maintenance: Subjects will be required to maintain their normal diet and physical activity habits during the study. Following the baseline trial, subjects will be provided with a scale and asked to weigh themselves at home on a daily basis. If body weight changes ±2kg from their initial weight, subjects will consult with our research dietitian for strategies to maintain weight during the period between study trials.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date February 28, 2020
Est. primary completion date February 28, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Subject Inclusion Criteria - Age: 18-40 - (Body Mass Index =27 kg/m2>27) - Women must have regularly occurring menses and must be premenopausal - Meet general blood donation eligibility requirements Subject Exclusion Criteria - Evidence/history of cardiovascular or metabolic disease - Medications known to affect lipid or glucose metabolism, or inflammation - Blood donation in the last 12 months - Iron supplementation in the last 12 months (multivitamin with =100 %DV ok) - Diagnosed anemia in the last 24 months - Weight instability = ±3kg in the last 6 months - Women must not be pregnant or actively lactating

Study Design


Intervention

Procedure:
Blood Donation
Subjects will donate blood within ~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.

Locations

Country Name City State
United States Michigan Clincal Research Unit Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in insulin sensitivity after blood donation A hyperinsulinemic-euglycemic clamp will be used to assess insulin sensitivity. The change in the glucose infusion rate will be used to measure the insulin sensitivity after blood donation. 1 month
Secondary Change in lipolytic rate after blood donation rate of appearance of glycerol 1 month
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4